Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer biomarkers.
Henry NL, Hayes DF. Henry NL, et al. Among authors: hayes df. Mol Oncol. 2012 Apr;6(2):140-6. doi: 10.1016/j.molonc.2012.01.010. Epub 2012 Feb 6. Mol Oncol. 2012. PMID: 22356776 Free PMC article. Review.
Tumor markers for breast cancer.
Hayes DF. Hayes DF. Ann Oncol. 1993 Dec;4(10):807-19. doi: 10.1093/oxfordjournals.annonc.a058385. Ann Oncol. 1993. PMID: 8117599 Free article. Review.
New prognostic factors for breast cancer recurrence.
Isaacs C, Stearns V, Hayes DF. Isaacs C, et al. Among authors: hayes df. Semin Oncol. 2001 Feb;28(1):53-67. doi: 10.1016/s0093-7754(01)90045-4. Semin Oncol. 2001. PMID: 11254867 Review.
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. Stearns V, et al. Among authors: hayes df. Clin Cancer Res. 2004 Dec 15;10(24):8332-40. doi: 10.1158/1078-0432.CCR-04-0297. Clin Cancer Res. 2004. PMID: 15623610 Clinical Trial.
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Dressler LG, et al. Among authors: hayes df. J Clin Oncol. 2005 Jul 1;23(19):4287-97. doi: 10.1200/JCO.2005.11.012. J Clin Oncol. 2005. PMID: 15994142
482 results